Phaseline

Companies › Galderma R&D

Galderma R&D: clinical trials, targets and expected readouts

2 active drug programs in 7 registered trials: 4 Phase 3, 3 Phase 2; Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nemolizumab
Interleukin-31 receptor subunit alpha inhibitor
IL31RAPhase 3Moderate-to-Severe Atopic Dermatitis; Prurigo Nodularis; Atopic Dermatitis; Chronic Pruritus of Unknown Origin …Dec 2026
Trifarotene
Retinoic acid receptor gamma agonist
RARGPhase 3Acne VulgarisDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03989206NemolizumabPhase 3Moderate-to-Severe Atopic DermatitisImmunologyAug 2026
NCT04204616NemolizumabPhase 3Prurigo NodularisImmunologyOct 2026
NCT07074977NemolizumabPhase 2Chronic Pruritus of Unknown OriginImmunologyDec 2026
NCT07186413TrifarotenePhase 3Acne VulgarisImmunologyDec 2026
NCT07762833NemolizumabPhase 3Atopic DermatitisImmunologyOct 2027
NCT07047690NemolizumabPhase 2Systemic SclerosisImmunologyMay 2028
NCT07660835NemolizumabPhase 2Moderate-to-Severe Atopic DermatitisImmunologyJul 2028

From the company's SEC filings

Complete response letters from FDA

Targets

IL31RA (1) RARG (1)

Companies with the same targets

IR INNOVATE RESEARCH PRIVATE HighField Biopharmaceuticals

Companies built like this

LEO Pharma Integrative Skin Science and Research Pharvaris Netherlands Chengdu Kangnuoxing Biopharma AUG Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.